Navigation Links
MIGENIX Corporate Update and Requisition of Special Meeting
Date:7/8/2008

s after approval of the product. This is a significant value opportunity for MIGENIX and was made possible only through the perseverance and commitment of the current management team and board of directors. Those knowledgeable about the biotech industry and the product development process understand that clinical success is required for value creation in drug development companies. We are no exception and have confidence in our strategy and in our ability to continue following through with the value opportunities we have created, regardless of the challenges inherent in this industry."

Program Update

Management and the Board have built a solid portfolio (pipeline) of programs to maximize value potential and mitigate development risk. The status of these programs is as follows:

Omigard(TM) (1% topical omiganan pentahydrocloride for preventing catheter-related infections): Patient enrolment in the Phase III US and European registration clinical trial conducted by Cadence Pharmaceuticals (who is fully funding the Omigard development program) is complete (see May 6, 2008 press release). Cadence expects to announce top-line data from this trial in the second half of 2008 and, with positive results, submit a new drug application for Omigard(TM) to the FDA in the first half of 2009. Upon successful completion of various milestones in this program (starting with FDA acceptance of the NDA for filing), we can receive up to US$27MM in development and commercialization milestone payments and a double-digit royalty on net sales. Cadence's commercialization focus is on the United States market and thus Cadence intends to establish a strategic partnership(s) for the commercialization of Omigard(TM) for the rights it has outside of the United States. MIGENIX management and Board are working to out-license Omigard(TM) rights either in combination with Cadence's rights outside the US to prospective global partners or to potential regional partners for rest of wor
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
3. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
4. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
7. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
8. MIGENIX releases CEO message #22
9. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
11. MIGENIX Appoints Pieter Dorsman to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Inc. Magazine ... States, ranking iLab Solutions as number 1,361 in growth for the three years through ... the top 0.1% fastest-growing privately held organizations in the country. , “We are ...
(Date:8/27/2015)... Irvine, CA (PRWEB) , ... August 27, 2015 ... ... leader in Personalized Medicine, recently presented new data on the relationship of genetics ... 2015 20th World Congress on Heart Disease in Vancouver, British Columbia, Canada. The ...
(Date:8/26/2015)...  Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... for the detection of foodborne pathogens, today announced that ... & Company Emerging Growth Conference on September 2 at ... New York Marriott Marquis. A live ... investor relations section of Roka Bioscience,s website at ...
(Date:8/26/2015)...  Platform therapeutic company Symic Biomedical, Inc. ("Symic") ... Phase II SBIR grant from the National Institutes ... agent to reduce arteriovenous fistula (AVF) failures, a ... disease (ESRD) patients undergoing hemodialysis. The two-year project, ... Digestive and Kidney Diseases (NIDDK), will allow Symic ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
... 2009, Platoon Fitness is holding Platoon University at Bryn Mawr Outdoor ... , BRYN MAWR, Pa., June 5 Platoon Fitness is ... certifying trainers from around the country in its outdoor training methods. ... exciting new techniques in the realm of outdoor fitness. Over 1100 ...
... FRANCISCO, Calif., June 5 Poniard Pharmaceuticals, Inc. (Nasdaq: ... innovative oncology therapies, today announced that Jerry McMahon, Ph.D., ... overview at the 8th Annual Needham Life Sciences Conference ... in New York. , , Dr. ...
... 5 Dendreon Corporation (Nasdaq: DNDN ) today announced that ... , Goldman Sachs 30th Annual Global Healthcare Conference, ... 8th Annual Needham Life Sciences Conference, ... The presentations will be audio webcast live and available for replay ...
Cached Biology Technology:Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference 2
(Date:8/20/2015)... CT ., Aug. 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces it has joined The Smart Card Alliance and ... Smart Card Alliance and the Smart Card Alliance Latin ... visibility to industry peers and thought leaders promoting adoption ...
(Date:8/12/2015)... 12, 2015   MedNet Solutions , an innovative ... of clinical research, is proud to announce that ... SaaS-based eClinical technology platform, has led the way to ... quarters of 2015.   Q2 2015 and Q1 2015 ... by contract value sold in the company,s 15 year ...
(Date:8/10/2015)... , August 10, 2015 ... Eye Tracking Technology for more than two decades, announces ... for integration into all consumer display formats. The SMI ... integration of eye tracking into consumer tablets, laptops, desktop ... smart glasses. Omnivision,s leading sensor technology contributes to the ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... Scientists can learn how advances in catalysis are addressing ... upcoming symposium at the 236th American Chemical Society national ... the contributions of the late Mike White at the ... "Catalysis is particularly important when it comes to energy ...
... MONICA, Calif., Aug. 18 NeuralIQ, a developer ... the,expansion of its global leadership team, headed by ... Blanks, former Executive Vice President of Sales ... the helm of NeuralIQ as the,company continues to ...
... University Park, Pa. -- A little known fungus tucked ... the insect munch through the hardest of woods according ... the discovery could lead to innovative methods of controlling ... of breaking down plant biomass for generating biofuels. ...
Cached Biology News:Catalysis takes center stage at chemistry conference 2Catalysis takes center stage at chemistry conference 3NeuralIQ Expands Global Leadership Team, Names Donnie Blanks CEO 2NeuralIQ Expands Global Leadership Team, Names Donnie Blanks CEO 3Novel fungus helps beetles to digest hard wood 2Novel fungus helps beetles to digest hard wood 3
... 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose Pale yellow solid. An ... a nitric oxide donor in pancreatic ... bacteria. Causes DNA alkylation and DNA ... Purity: ≥95% by HPLC. Soluble in ...
... HDAC4 - ChIP Grade HDAC4 is ... histone deacetylases, which consists of 1084 amino ... similar to the deacetylase domain of yeast ... the nucleus and cytoplasm in a process ...
Our Histology, Immunohistochemistry and tissue arrays services include samples processing, different type of staning, histollogical stains, image analysis, tissue arrays, immunohistochemistry, etc....
Mouse monoclonal antibody raised against a partial recombinant FBXO24. NCBI Entrez Gene ID = FBXO24...
Biology Products: